Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Relative potency (compared to biosimilar) of originators in ADCC and CDC assays

From: Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions

Assay Originator Relative potency CV
ADCC 2 140% 9.9%
  3 141% 11.1%
  4 135% 16.8%
CDC 2 92% 15.1%
  3 89% 10.2%
  4 89% 16.7%